JNK and cardiometabolic dysfunction

Area of Science:

• Biomedical Science
• Molecular Biology
• Cardiovascular Research

Background:

• Cardiometabolic syndrome (CMS) is a complex cluster of diseases including impaired glucose tolerance, obesity, dyslipidemia, and hypertension.
• CMS affects over 25% of the global population and significantly increases the risk of cardiovascular diseases like atherosclerosis and myocardial infarction.
• Understanding the molecular signaling pathways underlying CMS is crucial for developing effective treatments.

Purpose of the Study:

• To review the in vivo implications of c-Jun N-terminal Kinases (JNK) signaling in Cardiometabolic Syndrome (CMS).
• To evaluate the potential of targeting JNK pathways as a therapeutic strategy for CMS.
• To highlight the importance of JNK pathway research given the complexity and rising prevalence of CMS.

Main Methods:

• Literature review focusing on in vivo studies of JNK signaling in relation to CMS components.
• Analysis of current research on the role of JNK pathways in metabolic and cardiovascular dysregulation.
• Synthesis of findings to assess JNK as a therapeutic target.

Main Results:

• JNK signaling pathways have been implicated in the development and progression of various CMS conditions.
• Evidence suggests that modulating JNK activity could impact multiple facets of CMS.
• The complexity of CMS necessitates a detailed understanding of JNK's role across different tissues.

Conclusions:

• JNK signaling is a relevant target for therapeutic intervention in Cardiometabolic Syndrome.
• Further research into the specific roles of JNK pathways in vivo is warranted.
• Targeting JNK may offer a strategy for addressing the multifaceted nature of CMS.